The new Navin Molecular facility will nearly double the overall capacity at the site to 420 m³. It will support existing commercial-scale projects and meet future demands as the company expands its global customer base.

The multi-purpose facility will add 200 m³ of manufacturing capacity utilizing different vessel types. It will be capable of undertaking a range of chemistries, including hazardous processes such as direct fluorination, cyanation, azide chemistry, cryogenic reactions, and high-pressure hydrogenation. The plant will include a high level of automated control, including a distributed control system (DCS), maximizing efficiency while reducing risks to employees and the environment.

The expansion will also increase the size and capacity of the site’s existing 21 CFR-complaint QC laboratory for in-process testing. A new process safety laboratory and a dedicated zero-liquid discharge (ZLD) effluent treatment plant will be constructed, complying with India’s optimum green building concepts including renewable energy generation and solvent containment.  A ground-breaking ceremony took place at the site in April 2024, and the project is scheduled to be completed by the end of 2025.

“As our business expands, we are progressing numerous projects to increase in scale towards commercial manufacturing, as well as investing in new, more advanced and niche technologies that we had previously identified as growth opportunities. Combined, this additional capacity and broadened technology platform will not only satisfy these growing volumes, but will build for the future enabling us to capitalise on both horizontal and vertical market openings”, said Rajendra Kumar Sahu, Chief Executive Officer of Navin Molecular. “The new facility has been designed with sustainability at its core to minimise its environmental impact, while allowing us to continue to provide the highest quality, cost-effective manufacturing solutions for our customers.”

Navin Molecular was launched in 2023 and is the CDMO division of Navin Fluorine, focussed on supporting global pharmaceutical innovators. Its state-of-the-art site in Dewas offers process research and development through to commercial manufacturing of a wide range of regulatory starting materials and API intermediates.